Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Gain Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ONGOING PHASE 1B TRIAL OF GT-02287 TO BE EXTENDED BY AN ADDITIONAL NINE MONTHS FOR PARTICIPANTS WHO ENROLLED IN THE ORIGINAL THREE-MONTH STUDY DESIGN THE INDEPENDENT DATA MONITORING COMMITTEE (DMC) MET RECENTLY AND RECOMMENDED TO CONTINUE THE STUDY WITH NO CHANGES TO STUDY DESIGN BETHESDA, MD., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THE COMPANY HAS RECEIVED APPROVAL FROM THE BELLBERRY HUMAN RESEARCH ETHICS COMMITTEE AND ALFRED HOSPITAL ETHICS COMMITTEE TO EXTEND DOSING BY AN ADDITIONAL NINE MONTHS IN ITS ONGOING PHASE 1B CLINICAL STUDY OF GT-022887, BEYOND THE 90-DAY PERIOD CURRENTLY ALLOWED IN PROTOCOL.

GAIN THERAPEUTICS RECEIVES AUSTRALIAN APPROVAL OF PHASE 1B DOSING EXTENSION AND REPORTS POSITIVE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDATION

REACHED FULL ENROLMENT OF PHASE 1B STUDY EVALUATING GT-02287 IN PARKINSON'S DISEASE (PD) WITH OR WITHOUT GBA1 MUTATIONS DURING 2Q 2025, EARLIER THAN ANTICIPATED ANALYSIS OF FUNCTIONAL CHANGES AND BIOMARKER ACTIVITY AT 90 DAYS WILL BE AVAILABLE DURING 4Q 2025 IN JULY 2025 FOLLOWING THE CLOSE OF 2Q 2025, GAIN COMPLETED AN UNDERWRITTEN PUBLIC OFFERING THAT RESULTED IN APPROXIMATELY $7.1 MILLION OF NET PROCEEDS BETHESDA, MD., AUG. 12, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

GAIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2025 AND PROVIDES CORPORATE UPDATE

BETHESDA, MD., JULY 24, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT-GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN A FIRESIDE CHAT AND ONE-ON-ONE MEETINGS AT BTIG'S ANNUAL VIRTUAL BIOTECHNOLOGY CONFERENCE, BEING HELD TUESDAY, JULY 29TH THROUGH WEDNESDAY, JULY 30TH.

GAIN THERAPEUTICS TO PRESENT AT BTIG ANNUAL VIRTUAL BIOTECHNOLOGY CONFERENCE

BETHESDA, MD., JULY 16, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 4,501,640 SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE UP TO AN AGGREGATE OF 2,250,820 SHARES OF ITS COMMON STOCK. THE PUBLIC OFFERING PRICE FOR EACH SET OF TWO SHARES OF COMMON STOCK AND ACCOMPANYING WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK IS $3.11 PER SET OF SECURITIES, YIELDING AN EFFECTIVE PRICE OF $1.55 PER SHARE AND $0.01 PER WARRANT. THE WARRANTS ARE BEING SOLD AT THE RATE OF ONE WARRANT FOR EVERY TWO SHARES OF COMMON STOCK. THE WARRANTS WILL HAVE AN EXERCISE PRICE OF $1.65 PER SHARE, ARE EXERCISABLE IMMEDIATELY UPON ISSUANCE AND WILL EXPIRE FIVE YEARS FOLLOWING THE DATE OF ISSUANCE.

GAIN THERAPEUTICS ANNOUNCES PRICING OF $7.0 MILLION PUBLIC OFFERING

BETHESDA, MD., JULY 15, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THAT IT IS PROPOSING TO OFFER AND SELL, SUBJECT TO MARKET CONDITIONS, SHARES OF ITS COMMON STOCK (OR COMMON STOCK EQUIVALENTS IN LIEU THEREOF) AND WARRANTS TO PURCHASE COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING. GAIN EXPECTS TO GRANT THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF COMMON STOCK AND/OR THE WARRANTS OFFERED IN THE OFFERING. ALL OF THE SECURITIES ARE BEING OFFERED BY THE COMPANY.

GAIN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

AS OF JUNE 30 TH , 16 PARTICIPANTS HAVE ENROLLED IN THE PHASE 1B, AHEAD OF THE ORIGINAL GOAL OF AT LEAST 15 TOTAL PARTICIPANTS BY 3Q 2025

GAIN THERAPEUTICS ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 1B CLINICAL STUDY EVALUATING GT-02287 IN PEOPLE WITH PARKINSON'S DISEASE WITH OR WITHOUT A GBA1 MUTATION

BETHESDA, MD., JUNE 10, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED THAT GENE MACK, PRESIDENT AND CEO OF GAIN, WILL PRESENT AT TWO UPCOMING INVESTOR CONFERENCES: H.C.

GAIN THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

BETHESDA, MD., MAY 29, 2025 (GLOBE NEWSWIRE) -- GAIN THERAPEUTICS, INC. (NASDAQ: GANX) (GAIN, OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY LEADING THE DISCOVERY AND DEVELOPMENT OF THE NEXT GENERATION OF ALLOSTERIC SMALL MOLECULE THERAPIES, TODAY ANNOUNCED AN ORAL PRESENTATION AT THE GBA1 MEETING 2025, BEING HELD JUNE 5TH-7TH IN MONTREAL, CANADA.

GAIN THERAPEUTICS ANNOUNCES ORAL PRESENTATION AT 2ND GBA1 MEETING

FIRST BIOMARKER ANALYSIS FROM PHASE 1B STUDY OF GT-02287 IN PARKINSON'S DISEASE EXPECTED MID-2025 FIRST BIOMARKER ANALYSIS FROM PHASE 1B STUDY OF GT-02287 IN PARKINSON'S DISEASE EXPECTED MID-2025

GAIN THERAPEUTICS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2025 AND PROVIDES CORPORATE UPDATE

GT-02287 PROTECTS DOPAMINERGIC NEURONS AGAINST MITOCHONDRIAL TOXIN MPP+ SUGGESTING AN ACTION ON MITOCHONDRIAL GCASE IN ADDITION TO ITS IMPROVEMENT OF LYSOSOMAL GCASE ACTIVITY GT-02287 PROTECTS DOPAMINERGIC NEURONS AGAINST MITOCHONDRIAL TOXIN MPP+ SUGGESTING AN ACTION ON MITOCHONDRIAL GCASE IN ADDITION TO ITS IMPROVEMENT OF LYSOSOMAL GCASE ACTIVITY

Gain Therapeutics, Inc.

GANX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Gain Therapeutics, Inc.

GANX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GANX